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Abstract
Background: The evolutionary stages of manufacturing have led us to conceptualize the use of Industry 4.0 for
COVID-19 (coronavirus disease 2019), powered by Industry 4.0 technologies. Using applications of integrated process
optimizations reliant on digitized data, we propose novel intelligent networks along the vaccine value chain. Vaccine 4.0
may enable maintenance processes, streamline logistics, and enable optimal production of COVID-19 vaccines. Vaccine
4.0 Framework: The challenge in applying Vaccine 4.0 includes the requirement of large-scale technologies for digitally
transforming manufacturing, producing, rolling-out, and distributing vaccines. With our framework, Vaccine 4.0 analytics
will target process performance, process development, process stability, compliance, quality assessment, and optimized
maintenance. The benefits of digitization during and post the COVID-19 pandemic include first, the continual assurance
of process control, and second, the efficacy of big-data analytics in streamlining set parameter limits. Digitization including
big data-analytics may potentially improve the quality of large-scale vaccine production, profitability, and manufacturing
processes. The path to Vaccine 4.0 will enhance vaccine quality, improve efficacy, and compliance with data-regulated
requirements. Discussion: Fiscal and logistical barriers are prevalent across resource-limited countries worldwide. The
Vaccine 4.0 framework accounts for expected barriers of manufacturing and equitably distributing COVID-19 vaccines. With
amalgamating big data analytics and biometrics, we enable the identification of vulnerable populations who are at higher risk
of disease transmission. Artificial intelligence powered sensors and robotics support thermostable vaccine distribution in
limited capacity regions, globally. Biosensors isolate COVID-19 vaccinations with low or limited efficacy. Finally, Vaccine 4.0
blockchain systems address low- and middle-income countries with limited distribution capacities. Conclusion: Vaccine 4.0
is a viable framework to optimize manufacturing of vaccines during and post the COVID-19 pandemic.
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Introduction
There has been rapid progress and advancement in the
development of vaccines during the coronavirus disease
2019 (COVID-19) pandemic.1 Until 10th October, 2021,
106 vaccines are in clinical trials with another 75 in preclinical phases, and 6 vaccines in early or limited use; 37
have reached the final stages of testing.1 We discuss the
implementation of a novel framework to manufacture and
distribute COVID-19 vaccines. We also highlight the utilization of Industry 4.0 technologies as scalable tools during
global pandemics and epidemics.
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Figure 1. Driving forces of human and technology-led Vaccine 4.0 technologies.

Vaccine 4.0 Framework
The 4 evolutionary stages of manufacturing have led us to
postulate Vaccine 4.0, a technology otherwise referred to as
Industry 4.0. Using the basic principle of digitization and
machines, we posit new intelligent networks along the vaccine value chain. These network help in predicting failures,
enable maintenance processes autonomously, self-organize
logistics, and react to changes in production. The potential
for Vaccine 4.0 is wide and many pharmaceutical companies may adopt technologies such as cyber-physical systems, cloud computing, automation, and big data analytics
to improve processes such as manufacturing and distribution (Figure 1).2-4 A central challenge emerges before
embarking on the path to Vaccine 4.0. Key technologies are
required for digital transformation in the manufacturing,
rolling-out, and distribution process. The economic benefits
of wide-scale investment must be preemptively calculated
by the chief financial officer or an accounting professional
for every stage computing the expected return on investment (ROI). The barriers may persist consisting of internal
validation of data and external data security issues, which
may hinder the complete embracement to digitization in
healthcare and pharmaceutical production processes.
Industry 4.0 technology is critical for machine-tomachine settings and is in sync with all regulations of the
concerned health sector. Pharmaceutical companies are
highly regulated, optimal for digitization, and may adopt
continuous process verification (CPV) through vaccine
manufacturing data validated and assessed against Food
and Drug Administration (FDA) or region-specific guidelines. CPV consists of (1) statistical process control techniques, (2) quality ascribing to incoming materials, in
process materials, and finished vaccines, (3) in-, on-, and
at- line controls, and (4) risk-based real-time approaches to

ensure the materials meet quality and control requirements.
The CPV dashboard may be color coded (orange vs green)
to provide status updates of the manufacturing process from
incoming materials to outgoing vaccines. Big data analytics
technology may be utilized to improve the quality of vaccines, profitability, and the entire manufacturing process.
For example, if 1 pharmaceutical company produces a batch
of vaccines with sub-standard raw materials detected upon
completion, data analytics provides a single view of the
manufacturing process.
Vaccine 4.0 analytics proposedly caters to (1) process
performance, (2) process development, (3) process stability,
(4) compliance, (5) quality assessment, and (6) optimized
maintenance. The immediate benefits of digitization during
the COVID-19 era are the continued assurance of process
control, and the proposal of Big Data (BD) analytics to
detect deviations from set parameter limits. The automatic
monitoring may optimize the offerings by pharmaceutical
companies of continuous data being validated against FDA
or region-specific guidelines, and promoting compliance
with the requirements in the concerned industry sector. The
path to Vaccine 4.0 will enhance quality, improve efficacy,
and improve compliance with the data-regulated regulatory
requirements. The first step is to identify all problems in the
manufacturing, storing, packaging, distributing, marketing,
and usage of vaccines. The second step is to universalize the
parameters of importance for similar health outbreaks in the
future, and determine how information technology (IT)
may aid in accessing data sources for worldwide application. The final step is to commence pilot projects of vaccine
4.0 in all continents across the globe with adequate budgeting, refined implementation, and ultimately speed rollout to
other sites. Our proposed framework sets the path to Vaccine
4.0 by introducing a valuable era of manufacturing.
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Equitable COVID-19 Vaccine
Distribution
In striving for equitable access to vaccines, 1 potential way
to reach low- and middle-income populations is through
biometric digital IDs. In the past, biometric companies have
partnered with telecom companies to develop biometric
solutions for identifying vulnerable populations in rural settings.5 This is a prime example of using digital tools to identify people who are lost to the system and provide them with
digital identities, given that around 1.1 billion people worldwide lack formal identities.6 Utilized in combination with
surveillance systems, this may help ensure that digitally
undocumented populations receive the COVID-19 vaccine.
Biometrics are also being piloted in the United Kingdom
(UK) for keeping track of those who have gained immunity
or tested positive for antibodies.7 Analyzing such data can
subsequently determine pockets of the population that may
be at higher risk of transmission. Vaccine tracing via biometrics and smartphone technology would be crucial in
enabling necessary follow-ups in the case of required
booster shots for the coronavirus vaccine. Rapid digital
contact tracing that facilitates algorithmic, risk-stratified
recommendations for quarantine or social distancing could
significantly slow down the spread and allow some muchneeded recuperation for many overburdened hospitals and
healthcare workers.8,9 To improve the current status quo of
vaccinations in the elderly and to relieve the socioeconomic encumbrance on our society, the role of inflammaging in vaccination response must be further explored
and understood.10 When analyzing the effect of age-related
factors such as immunosenescence and inflammaging on
immune response to vaccination in the elderly, we recommend systems biology approaches to identify biomarkers,
stratify subpopulations, and incorporate databases to ethically configure vaccination methods customized for the
elderly.11

Employing Biosensors Against the
COVID-19 Pandemic
Biosensing refers to the detection of biomolecules using
analytics devices (ie, biosensors) that combine the natural
biological component (ie, a cell, protein, or nucleic acid)
with a physiochemical detector.12 The most notable model
being used today is the glucose sensor which is used in clinical analysis and monitoring of the disease. Previously, several robust biosensors detecting antibodies have been
constructed to control various infectious diseases like
Malaria, Typhoid, HIV, and Adenovirus infection.13 Two
types of biosensors mainly chip-based and paper-based
biosensors offer enormous potential for quick clinical
determination. Material based, film-based or carbon-based
biosensors have additionally been presented for possible
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extension of use for COVID-19.14 Biosensors reliant on
antibody-catalyzed water oxidation pathways can also be
developed to identify antibodies of contagious diseases.13
Current trends in artificial intelligence include the
usage of bio sensing gadgets for immune cell analysis.15
Delicate recognition of COVID-19 antibodies by biosensors can become particularly significant for clinical recognition of humoral responses. Furthermore, the revolution
of Industry 4.0 can be leveraged to develop artificial intelligence (AI)-enabled sensors for shipment of perishable
vaccines that need to be stored at a certain temperature,
pertinent in the COVID-19 pandemic. These sensors
send signals when vaccines are defiled. Biosensor-based
immunoassays can improve the identification of microbial antigens, improve accuracy of antibody tests (ie,
false negatives and false positives), while multiplex location of host insusceptible reaction antibodies may improve
the general particularity.

Implementing Blockchain Technology
and Machine Learning to the
COVID-19 Vaccine Supply Chain
Distribution of COVID-19 vaccines can be bolstered by
artificial intelligence and machine learning applications for
fabricating and assembling a block chain supply system,
described in Figure 2. International health governing organizations will play an integral role in funding and providing
financial aid to facilitate the building of an efficient block
chain system. Distributing COVID-19 vaccine around the
globe would require circulating 7 to 18 billion doses and
block chain is fundamental to make it equitable. At least
60% to 70% of the population is required to have immunity
in order to break the chain of transmission. Essentially,
block chain will also help address issues like vaccine expiration and vaccine record hoaxes.16 In the past, the Center
for Disease Control and Prevention (CDC) highlighted the
occurrence of various kinds of fraudulent activities like the
illegal selling of federal government provided vaccines or
ancillary supplies, consumer fraud, theft, and forged
vaccines.17
The block chain system utilizes quick response (QR)
codes such as barcodes and serial numbers printed at each
level ensuring all stakeholders have complete openness
from the producer to end-purchaser on a publicly available
system. Block chain will also be fundamental for a fair
COVID-19 vaccine dispersion. A worldwide consortium
must be enforced to classify those in most need of COVID19 vaccination. To accomplish this worldwide ideal, rather
than a public or provincial ideal, immunization access will
fundamentally rely upon a data framework with the most
conceivable uprightness to avoid powers of personal stakes.
BD analytics can therefore be leveraged to identify certain
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Figure 2. Implementation of blockchain technology in the era of Industry 4.0 for digital supply chain and its multiple benefits.

hotspots in low- and middle-income countries, and among
vulnerable populations like the elderly and frontline healthcare workers.
The COVID-19 immunization supply chain data framework must be worked with continuous updates on variables
like vaccine stockpiling levels, temperature control, stockouts, and amounts of auxiliary supplies. This is vital in
figuring the most significant variables for vaccination
campaigns, which include immunizing and protecting the
population, halting the spread of COVID-19, and lastly, the
wastage rates of vaccines.

in developing countries. Third, the lack of skilled workers
to manage the complex industry 4.0 structures and lack of
capital expenditure are present. Despite these barriers of
use, the manufacturing of Industry 4.0 is primed by greater
use of sensors, machines, and IT systems in lesser developed countries. With an active policy framework, it is possible to nurture new knowledge and capabilities that support
Vaccine 4.0 in an effort to reduce inequalities in vaccine
production and distribution.18

Limitations and Barriers of Use in
Developing Countries

Vaccine 4.0 consists of digitizing the vaccine manufacturing process by continually monitoring development processes and optimizing maintenance. The framework is
applicable to high income and low to middle incomes countries as it accounts for manufacturing and distributing barriers by incorporating big data analytics and biometrics.19
The Vaccine 4.0 framework considers the potential Industry
4.0 technologies to ensure equitable global distribution and

First, due to the absence of working procedures and regulations in developing countries, impediments to the industry
4.0 technology are imminent. Second, there is a lack of
proper legislative measures to grow cloud computing,
cyber-security, artificial intelligence, and augmented reality

Conclusion

Sarfraz et al
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manufacturing of vaccines, which are necessary to eradicate
pandemics, current and upcoming.
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